Dublin, April 25, 2019 (GLOBE NEWSWIRE) -- The "Cell Therapy Market Size, Share, & Trends Analysis Report By Use (Clinical, Research), By Type (Stem & Non-stem Cells) By Therapy Type (Autologous, Allogenic), By Region, And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.
The global cell therapy market size is expected to reach USD 7.92 billion by 2025, rising at a CAGR of 5.34% during the forecast period.
Growing worldwide interest in discovering and development of advanced therapy medicinal products that are based on genes, tissues, or cells is likely to spur the growth of the market.
Companies and research communities are witnessed to invest heavily in isolation and culturing of a wide range of cell types, such as chondrocytes, keratinocytes, stem, cartilage, dermal papilla, and epithelial cells for development of cell therapies. Regulatory bodies are playing a crucial role in the growth of this market by enforcing new laws pertaining to product development and approval.
Moreover, U.S. FDA is engaged in keeping a check on practice of unauthorized therapies, which is also one of the major concerns in the market. Direct cell reprogramming is gaining attention as a novel therapeutic strategy owing to its efficacy and safety advantages.
Fortuna Fix, a privately-held company, aimed at becoming the first company to bring in the clinical use of patient's own neural stem cells, produced by direct reprogramming for replacement of lost neuronal tissue in neurotrauma and neurodegeneration. Such ongoing activities in this space are anticipated to bolster the revenue generation in the future. Presence of scientific concerns pertaining to the usage of these therapies necessitates further studies for validation of clinical findings.
Further key findings from the report suggest:
- Currently, there are less number of approved products for clinical use and withdrawal of several commercialized products. This has resulted in lesser share of the clinical usage segment in the market
- The research use segment is projected to exhibit a CAGR of 5.6% during the forecast period. Presence of a substantial number of R&D projects is boosting investments in cell therapy for research use, thereby bolstering the growth of the segment
- Based on therapy type, allogenic therapies will remain the most prominent segment throughout the forecast horizon. This is due to high price and large number of companies involved in development of allogenic therapies
- On the other hand, autologous therapies are expected to post a higher CAGR during the same period. Lack of donors and affordability are two key drivers contributing to the growth of this segment
- JCR Pharmaceuticals Co. Ltd.; Vericel Corporation; Osiris Therapeutics, Inc.; and MEDIPOST are some key players operating in the market. Companies are focusing in expanding their product portfolio and tapping into the potential of the market.
Key Topics Covered:
Chapter 1 Executive Summary
1.1 Market Snapshot
Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Data Analysis
2.3 Market Formulation & Validation
2.4 Approaches for Market Estimation
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Rise in number of clinical studies pertaining to the development of cellular therapies
3.1.1.2 Rising adoption of regenerative medicine
3.1.1.3 Introduction of novel platforms and technologies
3.1.2 Market restraint analysis
3.1.2.1 Ethical concerns related to stem cell research
3.1.2.2 Clinical issues pertaining to development & implementation of cell therapy
3.1.2.2.1 Manufacturing issues
3.1.2.2.2 Genetic instability
3.1.2.2.3 Stem cell culture condition
3.1.2.2.4 Stem cell distribution after transplant
3.1.2.2.5 Immunological rejection
3.1.2.2.6 Challenges associated with allogenic mode of transplantation
3.2 Penetration & Growth Prospect Mapping For Therapy Type, 2017
3.3 Stem Cells & Non-stem Cells Market-Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis - Porter's
Chapter 4 Stem Cells & Non-stem Cells Market Categorization: Use-type Estimates & Trend Analysis
4.1 Stem Cells & Non-stem Cells Market: Use-type Movement Analysis
4.2 Clinical-use
4.2.1 Stem cells & non-stem cells market for clinical-use, 2014 - 2025 (USD Million)
4.2.2 Cell therapy market (stem cells & non-stem cells) for clinical-use, by therapeutic area
4.2.2.1 Malignancies
4.2.2.1.1 Stem cell and non-stem cell market for malignancies, 2014 - 2025 (USD Million)
4.2.2.2 Muscoskeletal disorders
4.2.2.3 Autoimmune disorders
4.2.2.4 Dermatology
4.2.2.5 Others
4.2.3 Cell therapy market (stem cells & non-stem cells) for clinical-use, by cell type
4.2.3.1 Stem cell therapies
4.2.3.1.1 Stem cell therapies market, 2014 - 2025 (USD Million)
4.2.3.1.2 Bone marrow, blood, & umbilical cord-derived stem cell therapies
4.2.3.1.3 Adipose-derived stem cell therapies
4.2.3.1.4 Other stem cell therapies
4.2.3.2 Non-stem cell therapies
4.3 Research-use
Chapter 5 Stem Cells & Non-stem Cells Market Categorization: Therapy Type Estimates & Trend Analysis
5.1 Stem Cells & Non-stem Cells Market: Therapy Type Movement Analysis
5.2 Allogenic Therapies
5.3 Autologous Therapies
Chapter 6 Market Categorization: Regional Estimates & Trend Analysis, by Product
6.1 Stem Cells & Non-stem Cells Market Share By Regional, 2017 & 2025
6.2 North America
6.2.1 Cell therapy market (stem cells & non-stem cells) , 2014 - 2025 (USD Million)
6.2.2 U.S.
6.2.3 Canada
6.3 Europe
6.3.1 Cell therapy market (stem cells & non-stem cells) , 2014 - 2025 (USD Million)
6.3.2 Germany
6.3.3 U.K.
6.4 Asia Pacific
6.4.1 Cell therapy market (stem cells & non-stem cells) , 2014 - 2025 (USD Million)
6.4.2 China
6.4.3 Japan
6.5 Latin America
6.5.1 Cell therapy market (stem cells & non-stem cells) , 2014 - 2025 (USD Million)
6.5.2 Brazil
6.6 MEA
6.6.1 Cell therapy market (stem cells & non-stem cells) , 2014 - 2025 (USD Million)
6.6.2 South Africa
Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.2 Company Profiles
- Kolon TissueGene, Inc.
- JCR Pharmaceuticals Co., Ltd.
- MEDIPOST
- Osiris Therapeutics, Inc.
- Stemedica Cell Technologies, Inc.
- Cells for Cells
- NuVasive, Inc
- Fibrocell Science, Inc.
- Vericel Corporation
- PHARMICELL Co., Ltd
- ANTEROGEN.CO.,LTD
- Celgene Corporation
For more information about this report visit https://www.researchandmarkets.com/r/aqhhmo
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.